High sensitive C - Reactive protein: A novel biochemical markers and its role in coronary artery disease

Journal of Association of Physicians of India

Volumn 53, Issue JAN, 2005, Pages 25-32

  Mitra, B ^a   Panja, M ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIAGNOSTIC AGENT;

BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; INFLAMMATION; METHODOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; HUMANS; INFLAMMATION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 19844366493     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Wilkins J, Gallimore JR, Moore EG, Pepys MB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 1998;44:1358-61.
2. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998;35:745-53.
3. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-58.
4. Kapyaho K, Welin MG, Tanner P, Karkkainen T, Weber T. Rapid determination of C-reactive protein by enzyme immunoassay using two monoclonal antibodies. Scand J Clin Lab Invest 1989;49:389-93.
5. Eda S, Kaufmann J, Molwitz M, Vorberg E. A new method of measuring C-reactive protein, with a low limit of detection, suitable for risk assessment of coronary heart disease. Scand J Clin Lab Invest Suppl 1999;230:32-35.
6. Borque L, Bellod L, Rus A, Seco ML, Galisteo-Gonzalez F. Development and validation of an automated and ultrasensitive immunoturbidimetric assay for C-reactive protein. Clin Chem 2000;46:1839-42.
7. Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem 2000;46:461-68.
8. Aqel NM, Ball RY, Waldmann, et al. Monocytic origin of foam cells in human atherosclerotic plaques. Atheroscerosis 1984; 53: 265-71.
9. Stary Hl. Evolusion and progression of atherosclerotic lesion in coronary arteries of children and young adults. Atheroscerosis 1989;9:119-32.
10. Davis MJ, Thomas AC. Plaque fissuring- the cause of acute myocardial infarction.Sudden ischemic death and crescendo angina. Br Heart J 1985;53:363-73.
11. Ambrose JA, Winters SL, Stern A, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. JACC 1985;5:609-16.
12. Falk E . Why do plaque rupture ? Circulation 1992;86:III 36-42
13. Moreno PR, Falk E, Palacious IF, et al. Macrophage infiltration in acute coonary syndromes.Implication for plaque rupture. Circulation 1994;90:775-8.
14. Vanderwal AC, Becker AE, Vanderloo CM, et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is charectarized by an infiltatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
15. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular diseases: application to clinical and public health practice: a statement for health care professionals from the centers for diseases control and prevention and American Heart Association. Circulation 2003;107:499-511.
16. Zhu J, Quyyumi AA, Norman JE, et al. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J Am Coll Cardiol 1999;34:1738-43.
17. Zhu J, Nieto FJ, Horne BD, et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001;103:45-51.
18. Ridker PM, Glynn RJ, Hennekens CH. C-Reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction [see comments]. Circulation 1998;97:2007-11.
19. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
20. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of Creactive protein and serum amyloid a protein in severe unstable angina [see comments]. N Engl J Med 1994;331:417-24.
21. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-60.
22. Ferreiros ER, Boissonnet CP, Pizarro R, Merletti PF, Corrado G, Cagide A, Bazzino OO. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 1999;100:1958-63.
23. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. C-Reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 1998;31:1460-65.
24. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. C-Reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 1998.
25. Morrow D, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998;31:1460-65.
26. Bazzino O, Ferreirós ER, Pizarro R, et al. C-reactive protein and the stress tests for the risk stratification of patients recovering from unstable angina pectoris. Am J Cardiol 2001;87:1235-9.
27. Bolibar I, von Eckardstein A, Assmann G, et al. Shortterm prognostic value of lipid measurements in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. Thromb Haemost 2000;84:955-60.
28. Koenig W, Sund M, Fröhlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middleaged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
29. Haverkate F, Thompson SG, Duckert F. Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction. Results of the ECAT Angina Pectoris Study Group. Thromb Haemost 1995;73:561-7.
30. Moukarbel GV, Arnaout MS, Alam SE. C-reactive protein is a marker for a complex culprit lesion anatomy in unstable angina. Clin Cardiol 2001;24:506-10.
31. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998;82:515-8.
32. Milazzo D, Biasucci LM, Luciani N, et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 1999;84:459-61,A9.
33. Eisenberg MS, Chen HJ, Warshofsky MK, et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 2000;102:2100-4.
34. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group [see comments]. Lancet 1997;349:462-66.
35. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44.
36. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
37. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening [Opinion]. Clin Chem 2001;47:28-30.
38. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening [Opinion]. Clin Chem 2001;47:28-30.
39. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease [see comments]. Circulation 1998;97:425-28.
40. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group [see comments]. Lancet 1997;349:462-66.
41. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group [see comments]. Lancet 1997;349:462-66.
42. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published erratum appears in N Engl J Med; see comments]. 1997;336:973-79.
43. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women [see comments]. Circulation 1998;98:731-33.
44. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-16.
45. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-8.
46. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
47. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
48. Markwood TT, Kent SM, Coyle LC, et al. Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol) - a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intimamedia thickness. Am Heart J 2001;141:342-7.
49. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793-8.
50. Kennon S, Price CP, Mills PG, et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 2001;37:1266-70.
51. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 2003;92(suppl):10i-18i.